Investing
Nabi Biopharmaceuticals (NABI) and Third Point LLC Reach Agreement
Published:
From 13D TrackerYesterday morning, Nabi Biopharmaceuticals (Nasdaq: NABI) and dissident shareholder Third Point LLC announced that they have reached a settlement relating to a potential consent solicitation.Under the deal, Nabi Biopharmaceuticals has appointed two Third Point nominees, Jason Aryeh, founder and general partner of JALAA Equities, LP and Tim Lynch, president and CEO of NeuroStat Pharmaceuticals, Inc., to the company’s board of directors. In addition, Nabi Biopharmaceuticals will establish a strategic action committee to continue the company’s previously announced process of exploring strategic alternatives. The Third Point nominees’ will sit on the five member committee.As part of the settlement, Nabi Biopharmaceuticals has agreed to pay up to $250,000 of Third Point’s expenses and Third Point has agreed that it will not commence a consent solicitation or a proxy contest prior to the company’s 2007 annual meeting of shareholders.Third Point CEO, Daniel S. Loeb, said, “We are pleased to be able to work constructively with Nabi Biopharmaceuticals with the shared goal of enhancing the value of the company.”http://www.13dtracker.blogspot.com/
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.